 SOUTH SAN FRANCISCO, Calif., May 03, 2021 GLOBE NEWSWIRE -- Denali Therapeutics Inc. NASDAQ: DNLI, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier BBB for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2021, and provided business highlights. 